Autor: "Stock, Wendy" - OpacWWW

Skocz do pozycji: 1.

Tytuł:: Efficacy and toxicity of reduced vs. standard dose pegylated asparaginase in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia.
Autorzy:: Derman BA; Section of Hematology/Oncology, University of Chicago, Chicago, IL, USA.
Streck M; Simon Cancer Center, Indiana University Health, Indianapolis, IN, USA.
Wynne J; Section of Hematology/Oncology, University of Chicago, Chicago, IL, USA.
Christ TN; Department of Pharmacy, University of Chicago, Chicago, IL, USA.; Rush University Medical Center, Chicago, IL, USA.
Curran E; Section of Hematology/Oncology, University of Chicago, Chicago, IL, USA.
Stock W; Section of Hematology/Oncology, University of Chicago, Chicago, IL, USA.
Knoebel RW; Department of Pharmacy, University of Chicago, Chicago, IL, USA.; Pokaż więcej
Źródło:: Leukemia & lymphoma [Leuk Lymphoma] 2020 Mar; Vol. 61 (3), pp. 614-622. Date of Electronic Publication: 2019 Nov 04.
Typ publikacji:: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:: Antineoplastic Agents*/adverse effects
Precursor Cell Lymphoblastic Leukemia-Lymphoma*/drug therapy
Adult ; Asparaginase/adverse effects ; Child ; Humans ; Middle Aged ; Philadelphia Chromosome ; Polyethylene Glycols/adverse effects ; Reference Standards

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 2.

Tytuł:: A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia.
Autorzy:: Wang AY; Internal Medicine/Pediatric Residency Program, University of Chicago Medicine, Chicago, IL, USA.
Weiner H; Department of Medicine, Section of Hematology/Oncology, University of Chicago Medicine, 5841 S. Maryland, MC 2115, Chicago, IL, 60637-1470, USA.
Green M; Department of Medicine, Section of Hematology/Oncology, University of Chicago Medicine, 5841 S. Maryland, MC 2115, Chicago, IL, 60637-1470, USA.
Chang H; Karyopharm Therapeutics Inc, 85 Wells Avenue, Suite 210, Newton, MA, 02459, USA.
Fulton N; Department of Medicine, Section of Hematology/Oncology, University of Chicago Medicine, 5841 S. Maryland, MC 2115, Chicago, IL, 60637-1470, USA.
Larson RA; Department of Medicine, Section of Hematology/Oncology, University of Chicago Medicine, 5841 S. Maryland, MC 2115, Chicago, IL, 60637-1470, USA.
Odenike O; Department of Medicine, Section of Hematology/Oncology, University of Chicago Medicine, 5841 S. Maryland, MC 2115, Chicago, IL, 60637-1470, USA.
Artz AS; Department of Medicine, Section of Hematology/Oncology, University of Chicago Medicine, 5841 S. Maryland, MC 2115, Chicago, IL, 60637-1470, USA.
Bishop MR; Department of Medicine, Section of Hematology/Oncology, University of Chicago Medicine, 5841 S. Maryland, MC 2115, Chicago, IL, 60637-1470, USA.
Godley LA; Department of Medicine, Section of Hematology/Oncology, University of Chicago Medicine, 5841 S. Maryland, MC 2115, Chicago, IL, 60637-1470, USA.
Thirman MJ; Department of Medicine, Section of Hematology/Oncology, University of Chicago Medicine, 5841 S. Maryland, MC 2115, Chicago, IL, 60637-1470, USA.
Kosuri S; Department of Medicine, Section of Hematology/Oncology, University of Chicago Medicine, 5841 S. Maryland, MC 2115, Chicago, IL, 60637-1470, USA.
Churpek JE; Department of Medicine, Section of Hematology/Oncology, University of Chicago Medicine, 5841 S. Maryland, MC 2115, Chicago, IL, 60637-1470, USA.
Curran E; Department of Medicine, Section of Hematology/Oncology, University of Chicago Medicine, 5841 S. Maryland, MC 2115, Chicago, IL, 60637-1470, USA.
Pettit K; Department of Medicine, Section of Hematology/Oncology, University of Michigan Medicine, Ann Arbor, MI, USA.
Stock W; Department of Medicine, Section of Hematology/Oncology, University of Chicago Medicine, 5841 S. Maryland, MC 2115, Chicago, IL, 60637-1470, USA.
Liu H; Department of Medicine, Section of Hematology/Oncology, University of Chicago Medicine, 5841 S. Maryland, MC 2115, Chicago, IL, 60637-1470, USA. .; Pokaż więcej
Źródło:: Journal of hematology & oncology [J Hematol Oncol] 2018 Jan 05; Vol. 11 (1), pp. 4. Date of Electronic Publication: 2018 Jan 05.
Typ publikacji:: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:: Antineoplastic Agents/*therapeutic use
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Cytarabine/*therapeutic use
Leukemia, Myeloid, Acute/*drug therapy
Mitoxantrone/*therapeutic use
Adult ; Aged ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Cytarabine/administration & dosage ; Cytarabine/adverse effects ; Female ; Humans ; Leukemia, Myeloid, Acute/pathology ; Male ; Middle Aged ; Mitoxantrone/administration & dosage ; Mitoxantrone/adverse effects ; Remission Induction/methods